Site icon OncologyTube

BCR Signaling Inhibitors Extremely Active and Generally Well Tolerated ASH 2015

Brian T. Hill , MD, PhD Assistant Professor, Medicine, Case Western Reserve University School of Medicine (Cleveland Clinic) discusses how BCR Signaling Inhibitors Extremely Active and Generally Well Tolerated from ASH 2015

Exit mobile version